Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Cipla
McKinsey
Fish and Richardson
Baxter
Chubb
Cantor Fitzgerald
Boehringer Ingelheim
Chinese Patent Office
US Army
Accenture

Generated: August 24, 2017

DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

« Back to Dashboard

Claims for Patent: ► Subscribe

Title: Carbocyclic nucleoside hemisulfate and its use in treating viral infections
Abstract:The hemisulfate salt of (1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene- 1-methanol or a solvate of it is used in the treatment of viral infections.
Inventor(s): Brodie; Alastair Couper (London, GB), Jones; Martin Francis (Kneloworth, GB), Seager; John Frederick (Ware, GB), Wallis; Christopher John (Rayston, GB)
Assignee: Glaxo Wellcome Inc. (Research Triangle Park, NC)
Application Number:09/423,982
Patent Claims: 1. The hemisufate salt of (1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene- 1-methanol or a solvate thereof.

2. The compound as claimed in claim 1 in the form of a hydrate.

3. A method for the treatment of an HIV or HBV infection in a human host which comprises administering to said host an effective amount of a compound as claimed in claim 1.

4. A pharmaceutical formulation comprising a compound as claimed in claim 1 and a pharmaeutically acceptable carrier therefor.

5. A pharmaceutical formulation as claimed in claim 4 in the form of a tablet, a capsule, or liquid formulation.

6. A pharmaceutical formulation as claimed in claim 4 adapted for parenteral administration.

7. A dicarboxylate salt of (1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene- 1-methanol wherein said dicarboxylate is selected from the group consisting of glutarate, hemisuberate, adipate, fumarate, hemisebacate and pimelate.

8. The glutarate salt of (1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene- 1-methanol.

9. A process for the preparation-of the compound claimed in claim 1 which process comprises:

adding sulfuric acid to (1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene- 1-methanol in a stoichiometric ratio of approximately 1:2.

10. A process for the preparation of the compound claimed in claim 1 which process comprises:

adding to (1S,4R)-cis-4-2-cyclopentene-1-methanol sulfate (1:1 salt) to (1S,4R)-cis-4-2-cyclopentene-1-methanol in a substantially 1:1 molar ratio in solution.

11. The benzoate or salicylate salt of (1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene- 1 -methanol.

12. A process for the preparation of the compound claimed in claim 1 which process comprises adding (1) sulfuric acid to (2) a salt of (1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene- 1-methanol selected from the group consisting of succinate, glutarate, hemisuberate, adipate, fumarate, hemisebacate and pimelate salts and any mixtures thereof, or from the group consisting of benzoate and salicylate salts and any mixtures thereof, wherein said sulfuric acid (1) and said salt (2) are present in the stoichiometric ratio of 2:1 if said salt (2) is a 1:1 salt, and 1:1 if said salt (2) is a 2:1 salt.

13. A pharmaceutical formulation as claimed in claim 4, 5, or 6 additionally comprising one or more therapeutic agents selected from the group consisting of nucleoside HIV reverse transcriptase inhibitors, non-nucleoside HIV reverse transcriptase inhibitors, HIV protease inhibitors, immune modulators selected from the group consisting of interleukin II, erythyropoetin and tucaresol, and .alpha.-interferon.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Boehringer Ingelheim
Queensland Health
Cantor Fitzgerald
QuintilesIMS
Medtronic
Moodys
Harvard Business School
Cipla
Deloitte
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot